Form 4: Mersana CEO Disposes Shares, Options in Day One Merger

Mersana Therapeutics CEO Martin H. Huber Jr. disposed of all common stock, stock options, and restricted stock units following the company's merger with Day One Biopharmaceuticals.

Summary

• Mersana Therapeutics, Inc. merged with Emerald Merger Sub, Inc., a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc., effective January 6, 2026.
• Shareholders received $25.00 per share in upfront cash plus one non-tradeable Contingent Value Right (CVR) per share.
• Each CVR represents the right to receive up to an additional $30.25 in cash upon the achievement of specified milestones.
• Martin H. Huber Jr., President, CEO, and Director, disposed of 9,573 shares of common stock.
• Cash-Out Options (exercise price less than $25.00) were fully vested, cancelled, and converted into the Offer Price minus the exercise price.
• Out-of-the-Money (OTM) Options (exercise price equal to or greater than $25.00) were fully vested and exercisable until the Last Exercise Date; those not exercised were cancelled without consideration.
• Restricted Stock Units were cancelled and converted into the Offer Price.
• Following the merger, Martin H. Huber Jr. holds no beneficial ownership of Mersana Therapeutics securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for shareholders who received cash and CVRs, but negative for out-of-the-money option holders. The transaction is a completion of a merger, which is a definitive event, not an ongoing operational update.

Positives

• The merger provides Mersana shareholders with an immediate cash payment of $25.00 per share.
• Shareholders also receive potential future upside through Contingent Value Rights (CVRs) of up to $30.25 per CVR, tied to milestone achievements.
• Cash-Out Options were converted into cash, providing value to option holders whose exercise price was below the upfront cash consideration.
• Restricted Stock Units were converted into the Offer Price, providing liquidity to RSU holders.

Negatives

• Out-of-the-Money (OTM) Options, with exercise prices equal to or greater than $25.00, were cancelled without consideration if not exercised, resulting in a loss of potential value for the reporting person.
• The CVRs are non-tradeable, limiting liquidity and requiring specific milestones to be met for the additional $30.25 per CVR to be realized.
• Mersana Therapeutics ceases to exist as an independent publicly traded entity, becoming a wholly-owned subsidiary of Day One Biopharmaceuticals.

Risks

• The contingent value rights (CVRs) are subject to the achievement of specific milestones, meaning the full potential value of $30.25 per CVR is not guaranteed.
• The CVRs are non-tradeable, which means holders cannot sell them on the open market for liquidity.

Future Outlook

The filing indicates the completion of a merger, transforming Mersana Therapeutics into a wholly-owned subsidiary of Day One Biopharmaceuticals. The future outlook for former Mersana shareholders is tied to the performance of Day One Biopharmaceuticals and the achievement of milestones for the contingent value rights.

Industry Context

This merger represents consolidation within the biotechnology or pharmaceutical sector, where larger companies acquire smaller, often clinical-stage, firms for their pipeline assets or technology. The use of CVRs is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks/rewards.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech mergers is a standard practice, particularly when the acquired company has pipeline assets with uncertain future value. For example, Sanofi's acquisition of Principia Biopharma in 2020 included CVRs tied to the approval of tolebrutinib.
• The structure of upfront cash plus CVRs is comparable to other recent biotech acquisitions, such as Bristol Myers Squibb's acquisition of MyoKardia, which also included a significant upfront cash component.
• The cancellation of out-of-the-money options without consideration is a standard outcome in mergers where the acquisition price does not exceed the option's exercise price, reflecting that these options held no intrinsic value at the time of the transaction.

Management Changes

Stakeholder Impact

• Shareholders: Received upfront cash and contingent value rights, providing immediate value and potential future upside, but losing direct equity in Mersana.
• Employees (including management): Martin H. Huber Jr. disposed of all securities, indicating a change in his role or departure from the now-subsidiary company. Other employees' roles and compensation structures would likely be impacted by the acquisition.
• Company (Mersana): Ceases to be an independent public entity, becoming a subsidiary of Day One Biopharmaceuticals, Inc.

Next Steps

• Day One Biopharmaceuticals, Inc. will integrate Mersana Therapeutics, Inc. as a wholly-owned subsidiary.
• Future payments to CVR holders will depend on the achievement of specified milestones.

Key Dates

Keywords

Mersana Therapeutics, Day One Biopharmaceuticals, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Contingent Value Rights, MRSN, Biotechnology, Pharmaceuticals